149 related articles for article (PubMed ID: 31185527)
1. Tofacitinib: raising awareness of mycoses.
Dyer J; Morwood K; Choong K
Intern Med J; 2019 Jun; 49(6):805-806. PubMed ID: 31185527
[No Abstract] [Full Text] [Related]
2. Elderly-Onset Varicella Pneumonia in a Patient With Rheumatoid Arthritis Treated With Tofacitinib.
Abe N; Kudo T; Jodo S
Arthritis Rheumatol; 2018 Aug; 70(8):1233. PubMed ID: 29648682
[No Abstract] [Full Text] [Related]
3. Herpes zoster as a cause of atypical chronic ulcerations associated with tofacitinib.
Noell C; Arbeit R; Kanhoush R
Dermatol Online J; 2018 Jan; 24(1):. PubMed ID: 29469766
[TBL] [Abstract][Full Text] [Related]
4. [Tofacitinib].
Döker S; Dewenter M; El-Armouche A
Dtsch Med Wochenschr; 2014 May; 139(19):1003-8. PubMed ID: 24782154
[TBL] [Abstract][Full Text] [Related]
5. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
Curtis JR; Lee EB; Kaplan IV; Kwok K; Geier J; Benda B; Soma K; Wang L; Riese R
Ann Rheum Dis; 2016 May; 75(5):831-41. PubMed ID: 25902789
[TBL] [Abstract][Full Text] [Related]
6. [Relevance of involvement of tofacitinib in T cell subsets to clinical courses and adverse events in patients with rheumatoid arthritis].
Sonomoto K; Tanaka Y
Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(6):443-7. PubMed ID: 27118331
[TBL] [Abstract][Full Text] [Related]
7. In brief: Risk of pulmonary thromboembolism and death with tofacitinib.
Med Lett Drugs Ther; 2019 Aug; 61(1579):136. PubMed ID: 31581159
[No Abstract] [Full Text] [Related]
8. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies.
Wollenhaupt J; Silverfield J; Lee EB; Curtis JR; Wood SP; Soma K; Nduaka CI; Benda B; Gruben D; Nakamura H; Komuro Y; Zwillich SH; Wang L; Riese RJ
J Rheumatol; 2014 May; 41(5):837-52. PubMed ID: 24692527
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial.
Kremer JM; Kivitz AJ; Simon-Campos JA; Nasonov EL; Tony HP; Lee SK; Vlahos B; Hammond C; Bukowski J; Li H; Schulman SL; Raber S; Zuckerman A; Isaacs JD
Arthritis Res Ther; 2015 Apr; 17(1):95. PubMed ID: 25889308
[TBL] [Abstract][Full Text] [Related]
10. Reversible eruption of neurofibromatosis associated with tofacitinib therapy for rheumatoid arthritis.
Rischin A; De Silva T; Le Marshall K
Rheumatology (Oxford); 2019 Jun; 58(6):1111-1113. PubMed ID: 30753711
[No Abstract] [Full Text] [Related]
11. Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.
Li Z; An Y; Su H; Li X; Xu J; Zheng Y; Li G; Kwok K; Wang L; Wu Q
Int J Rheum Dis; 2018 Feb; 21(2):402-414. PubMed ID: 29314645
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.
Machado MAÁ; Moura CS; Guerra SF; Curtis JR; Abrahamowicz M; Bernatsky S
Arthritis Res Ther; 2018 Mar; 20(1):60. PubMed ID: 29566769
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
Vyas D; O'Dell KM; Bandy JL; Boyce EG
Ann Pharmacother; 2013 Nov; 47(11):1524-31. PubMed ID: 24285764
[TBL] [Abstract][Full Text] [Related]
14. Varicella zoster virus myelitis in a patient with rheumatoid arthritis treated by tofacitinib.
Itamiya T; Komai T; Tsuchida Y; Shoda H; Fujio K
Scand J Rheumatol; 2021 Jul; 50(4):319-321. PubMed ID: 32940139
[No Abstract] [Full Text] [Related]
15. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study.
McInnes IB; Kim HY; Lee SH; Mandel D; Song YW; Connell CA; Luo Z; Brosnan MJ; Zuckerman A; Zwillich SH; Bradley JD
Ann Rheum Dis; 2014 Jan; 73(1):124-31. PubMed ID: 23482473
[TBL] [Abstract][Full Text] [Related]
16. Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation.
Pérez-Román DI; Ortiz-Haro AB; Ruiz-Medrano E; Contreras-Yáñez I; Pascual-Ramos V
Rheumatol Int; 2018 Apr; 38(4):599-606. PubMed ID: 29264637
[TBL] [Abstract][Full Text] [Related]
17. Occurrence of Extensive Cutaneous Human Papillomavirus Infection After Initiation of Tofacitinib Therapy.
Brunet-Possenti F; Charpentier C; Bouhnik Y; Deschamps L; Descamps D; Moins-Teisserenc H; Descamps V
JAMA Dermatol; 2019 May; 155(5):629-631. PubMed ID: 30865238
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies.
Fleischmann R; Kremer J; Tanaka Y; Gruben D; Kanik K; Koncz T; Krishnaswami S; Wallenstein G; Wilkinson B; Zwillich SH; Keystone E
Int J Rheum Dis; 2016 Dec; 19(12):1216-1225. PubMed ID: 27451980
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary Cryptococcosis in the Setting of Tofacitinib Therapy for Psoriasis.
Seminario-Vidal L; Cantrell W; Elewski BE
J Drugs Dermatol; 2015 Aug; 14(8):901-2. PubMed ID: 26267737
[TBL] [Abstract][Full Text] [Related]
20. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]